Surmodics | SRDX - Equity Capital And Reserves


Surmodics reported $111.31M in Equity Capital and Reserves for its fiscal quarter ending in June of 2025.





Equity Capital And Reserves Change Date
Abbott USD 52.13B 1.3B Dec/2025
Align Technology USD 3.96B 44.68M Sep/2025
Anika Therapeutics USD 143.46M 3.34M Dec/2025
Arrowhead Research USD 568.42M 102.37M Dec/2025
Artivion USD 448.23M 9.54M Dec/2025
Baxter International USD 6.13B 1.11B Dec/2025
Boston Scientific USD 24.23B 1.58B Dec/2025
EDAP TMS EUR 23.32M 4.5M Sep/2025
Edwards Lifesciences USD 10.2B 340.3M Sep/2025
Haemonetics USD 911.45M 62.28M Dec/2025
Heron Therapeutics USD 13.28M 1.6M Dec/2025
J&J USD 81.54B 3.07B Dec/2025
Merit Medical Systems USD 1.58B 54.9M Dec/2025
Mesa Laboratories USD 186.69M 8.22M Dec/2025
Nektar Therapeutics USD 89.83M 4.75M Dec/2025
Option Care Health USD 1.33B 32.27M Dec/2025
Stryker USD 21.78B 594M Sep/2025
Surmodics USD 111.31M 7.59M Jun/2025
Trinity Biotech USD -54.72M 5.18M Sep/2025